Latest malaria vaccine news
Recent stories and articles on malaria vaccine developments around the world
(Click on headline to read the full story.)
Q&A: A partnership to eradicate malaria
April 3, 2014 – Two international health organizations at the forefront of fighting infectious diseases in the developing world are joining hands to try to produce an innovative vaccine to prevent malaria, which kills hundreds of thousands of people annually.
Researchers from Edinburgh Infectious Diseases have made vital steps forward in malaria vaccine development that pave way for protective therapy
February 17, 2014 – Scientists from the Institute of Immunology and Infection Research at the University of Edinburgh have made a significant contribution towards the development of a vaccine to prevent malaria.
Edinburgh Infectious Diseases
Phase 1 clinical trial begins for malaria vaccine candidate based on iBio's proprietary technology
February 10, 2014 – iBio, Inc., a leader in plant-based biotechnology for developing and manufacturing biological products, reported the initiation of a Phase 1 human safety and immunogenicity clinical study of a transmission-blocking malaria vaccine candidate. The vaccine candidate was produced on the company's proprietary iBioLaunch™ platform by the Fraunhofer USA Center for Molecular Biotechnology.
E.coli-based malaria transmission-blocking vaccine
January 15, 2014 – Scientists have discovered how to make a protein out of E.coli (Escherichia coli) that could lead to a new low-cost and highly effective malaria vaccine.
Malaria breakthrough may help vaccine development
January 11, 2014 – In a discovery that may aid vaccine design for a common form of malaria in India, scientists have found the strain in circulation attacks human red blood cells by clamping down on them with a pair of proteins. Earlier studies had suggested only one P. vivax protein binds to one protein on the surface of red blood cells.
The Times of India
Rise in R&D funding, precursor for malaria eradication in Africa
January 3, 2014 – Over the last two decades, there has been a five-fold increase in annual funding for malaria research and development (R&D) – from $131 million in 1993 to $610 million in 2011. A cursory look at funding trends in the global battle against malaria reveals that much of the increase took place after 2004, when support stood at $320 million.
'Cocktail' approach could lead to universal malaria vaccine
December 30, 2013 – By mixing a key surface protein from a number of different strains of the malaria parasite, researchers say they have improved the effectiveness of a potential vaccine against the disease spread by mosquitoes.
Medical News Today
Developing a malaria vaccine: New antibodies block signaling pathway vital to parasitic invasion
December 16, 2013 – There have been some monumental advances in eradicating malaria from the world as of late. The World Health Organization (WHO) recently released its World Malaria Report stating that the past decade has seen over 3.3 million lives saved from the sometimes deadly mosquito-borne disease. Furthering these prospects of ridding the world of malaria, a team of researchers from Singapore’s Nanyang Technological University (NTU) have created antibodies that could block a signaling pathway in the malaria parasite, and subsequently prevent infection.
Malaria vaccine offers new mode of protection against disease
November 28, 2013 – A novel malaria vaccine developed at Oxford University has shown promising results in the first clinical trial to test whether it can protect people against the mosquito-borne disease.
University of Oxford
Africa: New push on malaria
November 22, 2013 – Malaria researchers believe that better coordination and new technologies, such as the use of vaccines and sophisticated disease mapping, can inject new life into the ambitious goal of eradicating the deadly illness.
A new danger to Africans
November 18, 2013 – Africans may become susceptible to a type of malaria that they had long been thought to be immune to because the parasite appears to be evolving, scientists said last week.
The New York Times
Technology roadmap resets targets on malaria vaccines
November 14, 2013 – More efficacious malaria vaccines and those that could eliminate the disease in different settings should be available by 2030, according to the 2013 Malaria Vaccine Technology Roadmap, announced today in The Lancet.
Malaria vaccine could be ready by 2015
October 22, 2013 – The world’s first malaria vaccine could be available within the next 18 months, marking a major advance in efforts to eradicate a disease that kills more than half a million people, many of them children, every year.
Hope for a malaria vaccine
October 13, 2013 – The most ambitious clinical trial of a malaria vaccine has shown some effectiveness in children over an 18-month period. While its efficacy is modest, it is nonetheless a significant advance in the long struggle to control a disease that kills some 600,000 people a year, mostly children under the age of 5.
The New York Times
The long war
October 12, 2013 – On October 8th researchers announced progress in developing a vaccine against malaria. GlaxoSmithKline (GSK), a British pharmaceutical firm, said it would seek regulatory approval next year for this vaccine, called RTS,S. GSK and its charitable partner, the PATH Malaria Vaccine Initiative, also revealed new data showing the vaccine’s effect in children. This is good news, but RTS,S will not vanquish malaria by itself.
A shot against malaria
October 11, 2013 – Even through a crackled cellular connection from Durban, South Africa, the optimism can be heard in Dr. David Kaslow’s mild-mannered voice. “It’s been a fairly long road. Twenty-plus years in development. There’s been a lot of twists and turns.”
The New Yorker
GSK malaria vaccine could be available in three years
October 8, 2013 – GSK is ready to take the first step in getting the vaccine to market after promising trial results showing it was effective in protecting children and babies from malaria for up to 18 months.
First malaria vaccine moves a step closer to approval
October 8, 2013 – A malaria vaccine studied in more than 15,000 African children has been found to reduce the number of cases of disease by 27 to 46 percent.
UK firm seeks to market world's first malaria vaccine
October 8, 2013 – British drug maker GlaxoSmithKline is seeking regulatory approval for the world's first malaria vaccine after trial data showed that it had cut the number of cases in African children.
Africa: Malaria vaccine candidate reduces disease over 18 months of follow-up in late-stage study
October 7, 2013 – Durban, South Africa — Results from a large-scale Phase III trial, presented today in Durban at the Multilateral Initiative on Malaria Pan African Conference, show that the most clinically advanced malaria vaccine candidate, RTS,S, continued to protect young children and infants from clinical malaria up to 18 months after vaccination.
Hope of malaria vaccine by 2015 after successful trials
October 7, 2013 – A vaccine against malaria could be introduced in the world's worst-hit countries in 2015, after the latest trial of a treatment produced by Britain's biggest drug company reduced the number of cases of the disease experienced by babies.
Old drug, new tricks to fight malaria in West Africa
September 11, 2013 – A new way of using an old drug is proving to be a breakthrough in combating seasonal malaria in West Africa, which kills tens of thousands of children every year according to Medicins Sans Frontieres (MSF).
Thomson Reuters Foundations
Knocking down the malaria causing parasite
August 22, 2013 – Targeting the malaria parasite’s ability to make an iron-containing molecule, haem, might help create a vaccine against the disease and also lead to novel drug therapies for blocking infection and transmission, according to research from a team of Indian scientists that was published recently in PLOS Pathogens.
A malaria vaccine works, with limits
August 12, 2013 – A new type of malaria vaccine gave 100 percent protection against infection to a small number of volunteers in recent tests—but under conditions that would be nearly impossible to reproduce in the countries where most malaria victims live.
The New York Times